WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.

Disclosures for additional planners can be found here.

Predisposing statement

Faculty

Philippe Moreau, MD

University Professor of Clinical Hematology
Head, Hematology Department
University Hospital of Nantes
Nantes, France

Disclosures

Disclosure: Philippe Moreau, MD, has the following relevant financial relationships:
Advisor or consultant for: AbbVie; Amgen; Celgene; Janssen; Oncopeptides; Sanofi

Hermann Einsele, MD, PhD

Professor
Director of Internal Medicine
Universitätsklinikum Würzburg
Würzburg, Germany

Disclosures

Disclosure: Hermann Einsele, MD, PhD, has disclosed the following relevant financial relationships:
Advisor or consultant for: Amgen; Bristol Myers Squibb Company; Celgene; GlaxoSmithKline; Janssen; Sanofi
Speaker or a member of a speakers bureau for: Amgen; Bristol Myers Squibb Company; Celgene; GlaxoSmithKline; Janssen; Sanofi; Takeda
Grants for clinical research from: Amgen; Bristol Myers Squibb Company; Celgene; Janssen

Monique Minnema, MD, PhD

Professor of Hematology
University Medical Center Utrecht
Utrecht, The Netherlands

Disclosures

Disclosure: Monique Minnema, MD, PhD, has the following relevant financial relationships:
Advisor or consultant for: Alnylam; Cilag; Gilead; Janssen
Speaker or a member of a speakers bureau for: Bristol Myers Squibb Company
Other: Celgene (hospitality)

Paula Rodriguez Otero, MD, PhD

Consultant
Clinical Universidad de Navarra
University of Navarra
Pamplona, Spain

Disclosures

Disclosure: Paula Rodriguez Otero, MD, PhD, has the following relevant financial relationships:
Advisor or consultant for: Bristol Myers Squibb Company; Celgene; GlaxoSmithKline; Janssen; Oncopeptides
Speaker or a member of a speakers bureau for: Amgen; Bristol Myers Squibb Company; Celgene; Janssen; Sanofi

Giovanni Palladini, MD, PhD

Amyloidosis Research and Treatment Center
Fondazione IRCCS Policlinico San Matteo
Department of Molecular Medicine
University of Pavia
Pavia, Italy

Disclosures

Disclosure: Giovanni Palladini, MD, PhD, has the following relevant financial relationships:
Advisor or consultant for: Janssen
Speaker or a member of a speakers bureau for: Janssen; Pfizer; Siemens

Editor

Keisha Peters, MSc

Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Keisha Peters, MSc, has disclosed no relevant financial relationships.

Content Reviewer

Stephanie Corder, ND, RN, CHCP

Associate Director, Accreditation and Compliance

Disclosures

Disclosure: Stephanie Corder, ND, RN, CHCP, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

CPD

Spotlight on Multiple Myeloma and AL Amyloidosis: Where Are We Today?

Authors: Philippe Moreau, MD; Hermann Einsele, MD, PhD; Monique Minnema, MD, PhD; Paula Rodriguez Otero, MD, PhD; Giovanni Palladini, MD, PhD
CPD Released: 11/30/2021
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 11/30/2022

Start Activity

Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US healthcare professionals, specifically hematology/oncology specialists, cardiologists, and nephrologists.

The goal of this activity is to improve knowledge of clinical trial data on immunotherapeutic approaches for multiple myeloma (MM) and amyloid light chain (AL) amyloidosis, and improve competence and confidence in applying these data to determine an individualized course of care for patients with this disease.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Latest recommendations for the treatment of newly diagnosed MM
- Latest data with CAR T-cell therapies for relapsed/refractory (R/R) MM
- Latest data with bispecific antibodies for R/R MM
- Latest data with novel small molecule therapies for R/R MM
- Latest data with emerging treatment strategies for AL amyloidosis

Disclosures

Disclosures for additional planners can be found here.

Predisposing statement

Faculty

Philippe Moreau, MD

University Professor of Clinical Hematology
Head, Hematology Department
University Hospital of Nantes
Nantes, France

Disclosures

Disclosure: Philippe Moreau, MD, has the following relevant financial relationships:
Advisor or consultant for: AbbVie; Amgen; Celgene; Janssen; Oncopeptides; Sanofi

Hermann Einsele, MD, PhD

Professor
Director of Internal Medicine
Universitätsklinikum Würzburg
Würzburg, Germany

Disclosures

Disclosure: Hermann Einsele, MD, PhD, has disclosed the following relevant financial relationships:
Advisor or consultant for: Amgen; Bristol Myers Squibb Company; Celgene; GlaxoSmithKline; Janssen; Sanofi
Speaker or a member of a speakers bureau for: Amgen; Bristol Myers Squibb Company; Celgene; GlaxoSmithKline; Janssen; Sanofi; Takeda
Grants for clinical research from: Amgen; Bristol Myers Squibb Company; Celgene; Janssen

Monique Minnema, MD, PhD

Professor of Hematology
University Medical Center Utrecht
Utrecht, The Netherlands

Disclosures

Disclosure: Monique Minnema, MD, PhD, has the following relevant financial relationships:
Advisor or consultant for: Alnylam; Cilag; Gilead; Janssen
Speaker or a member of a speakers bureau for: Bristol Myers Squibb Company
Other: Celgene (hospitality)

Paula Rodriguez Otero, MD, PhD

Consultant
Clinical Universidad de Navarra
University of Navarra
Pamplona, Spain

Disclosures

Disclosure: Paula Rodriguez Otero, MD, PhD, has the following relevant financial relationships:
Advisor or consultant for: Bristol Myers Squibb Company; Celgene; GlaxoSmithKline; Janssen; Oncopeptides
Speaker or a member of a speakers bureau for: Amgen; Bristol Myers Squibb Company; Celgene; Janssen; Sanofi

Giovanni Palladini, MD, PhD

Amyloidosis Research and Treatment Center
Fondazione IRCCS Policlinico San Matteo
Department of Molecular Medicine
University of Pavia
Pavia, Italy

Disclosures

Disclosure: Giovanni Palladini, MD, PhD, has the following relevant financial relationships:
Advisor or consultant for: Janssen
Speaker or a member of a speakers bureau for: Janssen; Pfizer; Siemens

Editor

Keisha Peters, MSc

Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Keisha Peters, MSc, has disclosed no relevant financial relationships.

Content Reviewer

Stephanie Corder, ND, RN, CHCP

Associate Director, Accreditation and Compliance

Disclosures

Disclosure: Stephanie Corder, ND, RN, CHCP, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

For Physicians

The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).

Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

From Medscape Education

CPD

Spotlight on Multiple Myeloma and AL Amyloidosis: Where Are We Today?

Authors: Philippe Moreau, MD; Hermann Einsele, MD, PhD; Monique Minnema, MD, PhD; Paula Rodriguez Otero, MD, PhD; Giovanni Palladini, MD, PhDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CPD Released: 11/30/2021

Valid for credit through: 11/30/2022

processing....

Select Any Chapter to Begin

Did you know that around 10% to 15% of patients with multiple myeloma (MM) develop clinical evident amyloid light chain (AL) amyloidosis, but the reverse situation is very rare (around 0.4%)?

Page 1 of 21

Frontline Therapy for Patients With Multiple Myeloma: State-of-the-Art Management - Pre-Assessment

CPD Information

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient is intended or should be inferred.

The material presented here does not necessarily reflect the views of WebMD Global, LLC or companies that support educational programming on medscape.org. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Faculty and Disclosures

Faculty

Philippe Moreau, MD

Hermann Einsele, MD, PhD

Monique Minnema, MD, PhD

Paula Rodriguez Otero, MD, PhD

Giovanni Palladini, MD, PhD

Editor

Keisha Peters, MSc

Content Reviewer

Stephanie Corder, ND, RN, CHCP

Peer Reviewer

CPD

Spotlight on Multiple Myeloma and AL Amyloidosis: Where Are We Today?

Target Audience and Goal Statement

Disclosures

Faculty

Philippe Moreau, MD

Hermann Einsele, MD, PhD

Monique Minnema, MD, PhD

Paula Rodriguez Otero, MD, PhD

Giovanni Palladini, MD, PhD

Editor

Keisha Peters, MSc

Content Reviewer

Stephanie Corder, ND, RN, CHCP

Peer Reviewer

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Spotlight on Multiple Myeloma and AL Amyloidosis: Where Are We Today?

Select Any Chapter to Begin

Did you know that around 10% to 15% of patients with multiple myeloma (MM) develop clinical evident amyloid light chain (AL) amyloidosis, but the reverse situation is very rare (around 0.4%)?